Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3797-3805

  Pulido, David ^a   Torrent, Marc ^a   Andreu, David ^b   Nogues, M Victoria ^c   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c MRC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; RIBONUCLEASE; RNASE 3; RNASE 7; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; CELL PERMEABILIZATION; CONTROLLED STUDY; DEPOLARIZATION; ENZYME ACTIVITY; EPITHELIUM CELL; HOST RESISTANCE; IMMUNE RESPONSE; LEUKOCYTE; MYCOBACTERIUM; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; ENZYME ACTIVATION; EOSINOPHIL CATIONIC PROTEIN; GENES, SYNTHETIC; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM; RECOMBINANT PROTEINS; RIBONUCLEASES;

EID: 84880319676     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00428-13     Document Type: Article

References (81)

1. Dye C, Glaziou P, Floyd K, Raviglione M. 2012. Prospects for tuberculosis elimination. Annu. Rev. Public Health 14:3-16.
2. Martinson NA, Hoffmann CJ, Chaisson RE. 2011. Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc. Am. Thorac. Soc. 8:288.
3. Chiang CY, Yew WW. 2009. Multidrug-resistant and extensively drugresistant tuberculosis. Int. J. Tuberc. Lung Dis. 13:304-311.
4. Saiga H, Shimada Y, Takeda K. 2011. Innate immune effectors in mycobacterial infection. Clin. Dev. Immunol. 2011:347594.
5. Janssen S, Jayachandran R, Khathi L, Zinsstag J, Grobusch MP, Pieters J. 2012. Exploring prospects of novel drugs for tuberculosis. Drug Design Dev. Ther. 6:217-224.
6. De Groote MA, Huitt G. 2006. Infections due to rapidly growing mycobacteria. Clin. Infect. Dis. 42:1756-1763.
7. Brown-Elliott BA, Nash KA, Wallace RJ. 2012. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 25:545-582.
8. Elston D. 2009. Nontuberculous mycobacterial skin infections recognition and management. Am. J. Clin. Dermatol. 10:281-285.
9. Liu PT, Modlin RL. 2008. Human macrophage host defense against Mycobacterium tuberculosis. Curr. Opin. Immunol. 20:371-376.
10. Pinheiro RO, Salles JD, Sarno EN, Sampaio EP. 2011. Mycobacterium leprae-host cell interactions and genetic determinants in leprosy: an overview. Future Microbiol. 6:217-230.
11. Shin D-M, Jo E-K. 2011. Antimicrobial peptides in innate immunity against mycobacteria. Immune Netw. 11:245-252.
12. Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, Krutzik SR, Bloom BR, Ganz T, Modlin RL, Stenger S. 2006. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J. Immunol. 177:1864-1871.
13. Soehnlein O. 2009. Direct and alternative antimicrobial mechanisms of neutrophil-derived granule proteins. J. Mol. Med. 87:1157-1164.
14. Lasco TM, Turner OC, Cassone L, Sugawara I, Yamada H, McMurray DN, Orme IM. 2004. Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun. 72: 1147-1149.
15. Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, Adam E, Woerly G, Dombrowicz D, Capron M. 2009. TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood 113:3235-3244.
16. Mendez-Samperio P. 2008. Role of antimicrobial peptides in host defense against mycobacterial infections. Peptides 29:1836-1841.
17. Mendez-Samperio P. 2010. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides 31:1791-1798.
18. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. 2007. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J. Leukoc. Biol. 82:934-945.
19. Sonawane A, Santos JC, Mishra BB, Jena P, Progida C, Sorensen OE, Gallo R, Appelberg R, Griffiths G. 2011. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell. Microbiol. 13: 1601-1617.
20. Mendez-Samperio P, Miranda E, Trejo A. 2006. Mycobacterium bovis bacillus Calmette-Guerin (BCG) stimulates human beta-defensin-2 gene transcription in human epithelial cells. Cell. Immunol. 239:61-66.
21. Lehrer RI, Ganz T. 2002. Cathelicidins: a family of endogenous antimicrobial peptides. Curr. Opin. Hematol. 9:18-22.
22. Zanetti M. 2004. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75:39-48.
23. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC. 1999. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286:113-117.
24. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. 2011. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol. Rev. 35:1126-1157.
25. Fjell CD, Hiss JA, Hancock REW, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11:37-51
26. Kapoor R, Eimerman PR, Hardy JW, Cirillo JD, Contag CH, Barron AE. 2011. Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:3058-3062.
27. Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, Packe GE, Davidson RN, Griffiths CJ, Wilkinson RJ. 2007. Neutrophil-mediated innate immune resistance to mycobacteria. J. Clinical Invest. 117:1988-1994.
28. Akuthota P, Xenakis JJ, Weller PF. 2011. Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity? J. Innate Immun. 3:113-119.
29. Boix E, Torrent M, Sánchez D, Nogués MV. 2008. The antipathogen activities of eosinophil cationic protein. Current Pharm. Biotech. 9:141-152.
30. Boix E, Salazar VA, Torrent M, Pulido D, Nogués MV, Moussaoui M. 2012. Structural determinants of the eosinophil cationic protein antimicrobial activity. Biol. Chem. 393:801-815.
31. Malik A, Batra JK. 2012. Antimicrobial activity of human eosinophil granule proteins: involvement in host defence against pathogens. Crit. Rev. Microbiol. 38:168-181.
32. Spencer JD, Schwaderer AL, DiRosario JD, McHugh KM, McGillivary G, Justice SS, Carpenter AR, Baker PB, Harder J, Hains DS. 2011. Ribonuclease 7 is a potent antimicrobial peptide within the human urinary tract. Kidney Int. 80:175-181.
33. Koten B, Simanski M, Glaser R, Podschun R, Schroder JM, Harder J. 2009. RNase 7 contributes to the cutaneous defense against Enterococcus faecium. PLoS One 4:e6424. doi:10.1371/journal.pone.0006424.
34. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A. 1999. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin. Exp. Allergy 29:1172-1186.
35. Bystrom J, Amin K, Bishop-Bailey D. 2011. Analysing the eosinophil cationic protein: a clue to the function of the eosinophil granulocyte. Respir. Res. 12:10.
36. Monteseirin J, Vega A, Chacon P, Camacho MJ, El Bekay R, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J. 2007. Neutrophils as a novel source of eosinophil cationic protein in IgE-mediated processes. J. Immunol. 179:2634-2641.
37. Torrent M, Pulido D, Nogués MV, Boix E. 2012. Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog. 8:e1003005. doi:10.1371/journal.ppat .1003005.
38. Pulido D, Moussaoui M, Andreu D, Nogues MV, Torrent M, Boix E. 2012. Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure. Antimicrob. Agents Chemother. 56:2378-2385.
39. Torrent M, de la Torre BG, Nogues VM, Andreu D, Boix E. 2009. Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem. J. 421: 425-434.
40. Torrent M, Pulido D, De la Torre BG, Garcia-Mayoral MF, Nogues MV, Bruix M, Andreu D, Boix E. 2011. Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization. J. Med. Chem. 54:7.
41. Borelli V, Vita F, Shankar S, Soranzo MR, Banfi E, Scialino G, Brochetta C, Zabucchi G. 2003. Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis. Infect. Immun. 71:605-613.
42. Driss V, Hermann E, Legrand F, Loiseau S, Delbeke M, Kremer L, Guerardel Y, Dombrowicz D, Capron M. 2012. CR3-dependent negative regulation of human eosinophils by Mycobacterium bovis BCG lipoarabinomannan. Immunol. Lett. 143:202-207.
43. Vijayan VK, Reetha AM, Jawahar MS, Sankaran K, Prabhakar R. 1992. Pulmonary eosinophilia in pulmonary tuberculosis. Chest 101:1708-1709.
44. Kita H. 2011. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol. Rev. 242:161-177.
45. Castro AG, Esaguy N, Macedo PM, Aguas AP, Silva MT. 1991. Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils in vivo and are ingested by the attracted granulocytes. Infect. Immun. 59:3009-3014.
46. Harder J, Schroder JM. 2002. RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. J. Biol. Chem. 277:46779-46784.
47. Zhang J, Dyer KD, Rosenberg HF. 2003. Human RNase 7: a new cationic ribonuclease of the RNase A superfamily. Nucleic Acids Res. 31:602-607.
48. Zanger P, Holzer J, Schleucher R, Steffen H, Schittek B, Gabrysch S. 2009. Constitutive expression of the antimicrobial peptide RNase 7 is associated with Staphylococcus aureus infection of the skin. J. Infect. Dis. 200:1907-1915.
49. Simanski M, Köten B, Schröder JM, Gläser R, Harder J. 2012. Antimicrobial RNases in cutaneous defense. J. Innate Immun. 4:241-247.
50. Bernard JJ, Gallo RL. 2011. Protecting the boundary: the sentinel role of host defense peptides in the skin. Cell. Mol. Life Sci. 68:2189-2199.
51. Casanova JL, Abel L. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 20:581-620.
52. Jiang ZQ, Higgins MP, Whitehurst J, Kisich KO, Voskuil MI, Hodges RS. 2011. Anti-tuberculosis activity of alpha-helical antimicrobial peptides: de novo designed L-and D-enantiomers versus L-and D-LL37. Protein Peptide Lett. 18:241-252.
53. Boenickse R, Juhasz E. 1964. Description of the new species Mycobacterium vaccae n. sp. Zentralbl. Bakteriol. Orig. 192:133-135.
54. Skerman VBD, McGowan V, Sneath PHA. 1980. Approved lists of bacterial names. Int. J. Syst. Bacteriol. 30:225-420.
55. Boix E, Nikolovski Z, Moiseyev GP, Rosenberg HF, Cuchillo CM, Nogues MV. 1999. Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity. J. Biol. Chem. 274:15605-15614.
56. Buchan DWA, Ward SM, Lobley AE, Nugent TCO, Bryson K, Jones DT. 2010. Protein annotation and modeling servers at University College London. Nucleic Acids Res. 38:W563-W568.
57. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, P. A.
58. Torrent M, Badia M, Moussaoui M, Sanchez D, Nogues MV, Boix E. 2010. Comparison of human RNase 3 and RNase 7 bactericidal action at the Gram-negative and Gram-positive bacterial cell wall. FEBS J. 277: 1713-1725.
59. Torrent M, Navarro S, Moussaoui M, Nogues MV, Boix E. 2008. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47:3544-3555.
60. Singh A, Batra JK. 2011. Role of unique basic residues in cytotoxic, antibacterial and antiparasitic activities of human eosinophil cationic protein. Biol. Chem. 392:337-346.
61. Ho YS, Adroub SA, Abadi M, Al Alwan B, Alkhateeb R, Gao G, Ragab A, Ali S, van Soolingen D, Bitter W, Pain A, Abdallah AM. 2012. Complete genome sequence of Mycobacterium vaccae type strain ATCC 25954. J. Bacteriol. 194:6339-6340.
62. Koehne G, Maddux R, Britt J. 1981. Rapidly growing mycobacteria associated with bovine mastitis. Am. J. Vet. Res. 42:1238-1239.
63. Hachem R, Raad I, Rolston KVI, Whimbey E, Katz R, Tarrand J, Libshitz H. 1996. Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin. Infect. Dis. 23:173-175.
64. Sanchez D, Moussaoui M, Carreras E, Torrent M, Nogues V, Boix E. 2011. Mapping the eosinophil cationic protein antimicrobial activity by chemical and enzymatic cleavage. Biochimie 93:331-338.
65. Wang H, Schwaderer AL, Kline J, Spencer JD, Kline D, Hains DS. 2013. Contribution of structural domains to ribonuclease 7's activity against uropathogenic bacteria. Antimicrob. Agents Chemother. 57:766-774.
66. Andreu D, Ubach J, Boman A, Wahlin B, Wade D, Merrifield RB, Boman HG. 1992. Shortened cecropin-A melittin hybrids: significant size reduction retains potent antibiotic activity. FEBS Lett. 296:190-194.
67. Milani A, Benedusi M, Aquila M, Rispoli G. 2009. Pore forming properties of cecropin-melittin hybrid peptide in a natural membrane. Molecules 14:5179-5188.
68. García-Mayoral MF, Moussaoui M, de la Torre BG, Andreu D, Boix E; Nogués MV, Rico, M, Laurents, DV, Bruix M. 2010. NMR structural determinants of eosinophil cationic protein binding to membrane and heparin mimetics. Biophys. J. 98:2702-2711.
69. Torrent M, Di Tommaso P, Pulido D, Nogués M, Notredame C, Boix E, Andreu D. 2012. AMPA: an automated web server for prediction of protein antimicrobial regions. Bioinformatics 28:130-131.
70. Torrent M, Cuyas E, Carreras E, Navarro S, Lopez O, de la Maza A, Nogues MV, Reshetnyak YK, Boix E. 2007. Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 46:720-733.
71. Saugar JM, Rodriguez-Hernandez MJ, de la Torre BG, Pachon-Ibanez ME, Fernandez-Reyes M, Andreu D, Pachon J, Rivas L. 2006. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob. Agents Chemother. 50:1251-1256.
72. Torrent M, Odorizzi F, Nogues MV, Boix E. 2010. Eosinophil cationic protein aggregation: identification of an N-terminus amyloid prone region. Biomacromolecules 11:1983-1990.
73. Cemma M, Brumell JH. 2012. Interactions of pathogenic bacteria with autophagy systems. Curr. Biol. 22:R540-R545.
74. Mostowy S, Cossart P. 2012. Bacterial autophagy: restriction or promotion of bacterial replication? Trends Cell Biol. 22:283-291.
75. Chu HT, Pazgier M, Jung G, Nuccio SP, Castillo PA, de Jong MF, Winter MG, Winter SE, Wehkamp J, Shen B, Salzman NH, Underwood MA, Tsolis RM, Young GM, Lu WY, Lehrer RI, Baumler AJ, Bevins CL. 2012. Human alpha-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science 337:477-481.
76. Boix E, Pulido D, Moussaoui M, Nogues MV, Russi S. 2012. The sulfate-binding site structure of the human eosinophil cationic protein as revealed by a new crystal form. J. Struct. Biol. 179:1-9.
77. Gouet P, Courcelle E, Stuart DI, Metoz F. 1999. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15:305-308.
78. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. 2009. Jalview version 2: a multiple sequence alignment editor and analysis workbench. Bioinformatics 25:1189-1191.
79. Conchillo-Sole O, de Groot NS, Aviles FX, Vendrell J, Daura X, Ventura S. 2007. AGGRESCAN: a server for the prediction and evaluation of hot spots of aggregation in polypeptides. BMC Bioinform. 8:65.
80. Maurer-Stroh S, Debulpaep M, Kuemmerer N, de la Paz ML, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, Schymkowitz JWH, Rousseau F. 2010. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat. Methods 7:237-U109.
81. Huang YC, Lin YM, Chang TW, Wu SJ, Lee YS, Chang MD, Chen C, Wu SH, Liao YD. 2007. The flexible and clustered lysine residues of human ribonuclease 7 are critical for membrane permeability and antimicrobial activity. J. Biol. Chem. 282:4626-4633.